The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis

Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Naeem, Peters, Jayne, Davies, Elizabeth, Sharif, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660106/
https://www.ncbi.nlm.nih.gov/pubmed/38024590
http://dx.doi.org/10.1002/jha2.779
_version_ 1785137691913879552
author Desai, Naeem
Peters, Jayne
Davies, Elizabeth
Sharif, Joseph
author_facet Desai, Naeem
Peters, Jayne
Davies, Elizabeth
Sharif, Joseph
author_sort Desai, Naeem
collection PubMed
description Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of interleukin‐6 and has been used in the treatment of severe/critical coronavirus disease 2019 infection but also some cases of HHS. We describe two further cases of HHS successfully treated with tocilizumab and propose a decision aid for when to consider this treatment.
format Online
Article
Text
id pubmed-10660106
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106601062023-10-23 The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis Desai, Naeem Peters, Jayne Davies, Elizabeth Sharif, Joseph EJHaem Short Reports Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of interleukin‐6 and has been used in the treatment of severe/critical coronavirus disease 2019 infection but also some cases of HHS. We describe two further cases of HHS successfully treated with tocilizumab and propose a decision aid for when to consider this treatment. John Wiley and Sons Inc. 2023-10-23 /pmc/articles/PMC10660106/ /pubmed/38024590 http://dx.doi.org/10.1002/jha2.779 Text en © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Desai, Naeem
Peters, Jayne
Davies, Elizabeth
Sharif, Joseph
The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title_full The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title_fullStr The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title_full_unstemmed The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title_short The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
title_sort role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660106/
https://www.ncbi.nlm.nih.gov/pubmed/38024590
http://dx.doi.org/10.1002/jha2.779
work_keys_str_mv AT desainaeem theroleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT petersjayne theroleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT davieselizabeth theroleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT sharifjoseph theroleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT desainaeem roleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT petersjayne roleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT davieselizabeth roleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis
AT sharifjoseph roleoftocilizumabinthetreatmentofposttransfusionhyperhaemolysis

Ejemplares similares